Junho Jung1,2, Jung Soo Park3, Leonardo Righesso1, Andreas Max Pabst1,4, Bilal Al-Nawas1, Yong-Dae Kwon5, Christian Walter6,7. 1. Department of Oral and Maxillofacial Surgery, Plastic Surgery, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. 2. Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea. 3. Department of Periodontology, Korea University Anam Hospital, Seoul, Republic of Korea. 4. Department of Oral and Maxillofacial Surgery, Federal Armed Forces Hospital, Koblenz, Germany. 5. Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea. yongdae.kwon@gmail.com. 6. Department of Oral and Maxillofacial Surgery, Plastic Surgery, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. walter@mainz-mkg.de. 7. Oral and Maxillofacial Surgery - Facial Plastic Surgery, Mediplus Clinic, Mainz, Germany. walter@mainz-mkg.de.
Abstract
OBJECTIVE: To analyze the influence of an oral bisphosphonate and compare the potency to intravenous bisphosphonates on various cell types as regards the rarity of bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) caused by oral bisphosphonate. MATERIALS AND METHODS: A viability assay (MTT), a migration assay (Boyden chamber), and an apoptosis assay (Caspase-Glo® 3/7) were performed to analyze the effect of bisphosphonates on human fibroblasts, umbilical vein endothelial cells (HUVEC), and osteoblasts. RESULTS: Alendronate and intravenous bisphosphonates suppressed cell viability and migration, and induced apoptosis in all tested cell types. Alendronate had a greater impact than ibandronate on the characteristics in fibroblasts and osteoblasts but not as strong as zoledronate. CONCLUSIONS: The incidence of BP-ONJ in oral bisphosphonate treatment is reported to be much lower than that in intravenous bisphosphonates. However, the influences of alendronate on human cells were at least as strong as ibandronate, although it was lower than zoledronate. CLINICAL RELEVANCE: Alendronate showed strong enough effects to suppress human somatic cells and was comparable to certain intravenous bisphosphonates in potency. This study suggests that the lower incidence of BP-ONJ in alendronate treatment is not originated by its potency, but might be due to the low bioavailability of alendronate, lower dosing on a daily basis, and having no additional therapies.
OBJECTIVE: To analyze the influence of an oral bisphosphonate and compare the potency to intravenous bisphosphonates on various cell types as regards the rarity of bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) caused by oral bisphosphonate. MATERIALS AND METHODS: A viability assay (MTT), a migration assay (Boyden chamber), and an apoptosis assay (Caspase-Glo® 3/7) were performed to analyze the effect of bisphosphonates on human fibroblasts, umbilical vein endothelial cells (HUVEC), and osteoblasts. RESULTS:Alendronate and intravenous bisphosphonates suppressed cell viability and migration, and induced apoptosis in all tested cell types. Alendronate had a greater impact than ibandronate on the characteristics in fibroblasts and osteoblasts but not as strong as zoledronate. CONCLUSIONS: The incidence of BP-ONJ in oral bisphosphonate treatment is reported to be much lower than that in intravenous bisphosphonates. However, the influences of alendronate on human cells were at least as strong as ibandronate, although it was lower than zoledronate. CLINICAL RELEVANCE: Alendronate showed strong enough effects to suppress human somatic cells and was comparable to certain intravenous bisphosphonates in potency. This study suggests that the lower incidence of BP-ONJ in alendronate treatment is not originated by its potency, but might be due to the low bioavailability of alendronate, lower dosing on a daily basis, and having no additional therapies.
Entities:
Keywords:
Alendronate; BP-ONJ; Bisphosphonate; Bisphosphonate-associated osteonecrosis of the jaw; Fibroblasts; HUVEC; Osteoblasts
Authors: Sven Otto; Christoph Pautke; Daniel Arens; Philipp Poxleitner; Ursula Eberli; Dirk Nehrbass; Stephan Zeiter; Martin J Stoddart Journal: J Bone Miner Res Date: 2020-08-10 Impact factor: 6.741
Authors: Francisco Javier Manzano-Moreno; Rebeca Illescas-Montes; Lucia Melguizo-Rodriguez; Victor J Costela-Ruiz; Olga García-Martínez; Concepción Ruiz; Javier Ramos-Torrecillas Journal: Int J Med Sci Date: 2019-10-21 Impact factor: 3.738